entertainment -WSS

entertainment

author：leisure time 2025-08-12 08:27:44 - browse：928

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today, we explore the future of obesity drugs and how they’re named, we chat with CRISPR pioneers about what it’s like to see the technology approved for human use, and more.

The need-to-know this morning:
• Bayer said it prematurely stopped a Phase 3 study in stroke prevention after independent monitors concluded its experimental blood-thinning medicine, called asundexian, showed inferior efficacy compared to a standard treatment. The asundexian study setback is a significant blow to Bayer’s effort to revamp its drug-development pipeline, analysts said.
• Carmot Therapeutics filed paperwork Friday for an initial public offering of undisclosed size. The Berkeley, Calif.-based company is developing drugs that target GLP-1 and GIP to treat diabetes and obesity, similar to Novo Nordisk’s Ozempic/Wegovy and Eli Lilly’s Mounjaro/Zepbound.
• Bristol Myers Squibb and 2Seventy Bio said the FDA will not complete an on-time review of its application seeking to expand the use of Abecma, their CAR-T therapy for multiple myeloma. Instead, the FDA will convene an advisory panel meeting — date to be determined — to examine survival data from an Abecma clinical trial.
• The U.K. and the pharmaceutical industry have reached a deal on a five-year plan outlining how the health system pays for drugs, as the country tries to keep a lid on its medicines spending while simultaneously building up its life sciences industry. STAT’s Andrew Joseph has more here.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： My superpower is killing ticks

WSS

Biden calls for immediate release of Niger's president amid apparent coup

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

H5N1 bird flu: what we're starting to learn about infection in cows

Biden calls for immediate release of Niger's president amid apparent coup

Dairy farmers resist CDC push for PPE against bird flu virus

Software glitch causes Tandem insulin pump to shutdown, FDA warns

hotspot

entertainment

explore

In Memoriam: Notable people who died in 2023

The drug industry sees a key ally in the Senate prevail

At least 13 dead in Texas as scorching temps continue

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

United colonoscopy coverage change 'may cost lives,' doctors say

The drug industry sees a key ally in the Senate prevail

The high cost of giving birth even with insurance

Google says AlphaFold 3 can map a vast universe of biomolecules

ChatGPT in medicine: STAT answers readers' burning questions

Stem cell clinics for heart failure: buyer be wary

knowledge

White House drug shortage group privately met with industry

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

Attacks on the drug industry will lead to fewer breakthroughs

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

focus

entertainment

hotspot

focus